Journals / Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi / 2017 / Cilt: 31 - Sayı: 1

The Use of Diffusion Weighted Magnetic Resonance Imaging in The Differential Diagnosıs of Prostate Cancer and Benign Prostatic Hyperplasia

Prostat Kanseri ile Benign Prostat Hiperplazisinin Ayırıcı Tanısında Difüzyon Ağırlıklı Manyetik Rezonans Görüntülemenin Yeri

Pages
19–24
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Diffusion weighted echo-planar imaging and ADC measurements of prostate provides important informations in the differential diagnosis of prostate cancer and benign prostatic hyperplasia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: to measure and compare the prostate apparent diffusion coefficients (ADC) in patients with prostate cancer and benign prostatic hyperplasia by using diffusion weighted magnetic resonance imaging (MRI).
📊
Key Findings & Data:Material and Methods: Diffusion weighted echo-planar (EPI) MR imaging was performed to 20 patients with prostate cancer and 20 patients with benign prostatic hyperplasia.
💡
Conclusion & Impact:Conclusion: Diffusion weighted echo-planar imaging and ADC measurements of prostate provides important informations in the differential diagnosis of prostate cancer and benign prostatic hyperplasia.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: to measure and compare the prostate apparent diffusion coefficients (ADC) in patients with prostate cancer and benign prostatic hyperplasia by using diffusion weighted magnetic resonance imaging (MRI). Material and Methods: Diffusion weighted echo-planar (EPI) MR imaging was performed to 20 patients with prostate cancer and 20 patients with benign prostatic hyperplasia. ADCs of b600 and b1000 values were compared between the groups of patients with prostate cancer and patients with benign prostatic hyperplasia. Results: In patients with prostate cancer, mean ADC values that measured from patient prostates by guidance of prostate biopsy data, were 1.16x10-3±0.66x10-4 mm2/s and 1.87x10-4±2.09x105mm2/s for b600 and b1000 respectively. In patients with benign prostatic hyperplasia, mean ADC values that measured from patient prostates by randomize selection of prostate anatomic localization, were 1.71x10-3±1.96x10-4 mm2/s and 2.90x10-4±1.58x10-5 mm2/s for b600 and b1000, respectively. ADC values that obtained from each patient prostate were significantly lower in patient group with prostate cancer than the patient group with benign prostatic hyperplasia for b600 and b1000. Conclusion: Diffusion weighted echo-planar imaging and ADC measurements of prostate provides important informations in the differential diagnosis of prostate cancer and benign prostatic hyperplasia.

Özet

Amaç: Bu çalışmanın amacı, difüzyon ağırlıklı Manyetik Rezonans Görüntüleme (MRG) tekniğini kullanarak, prostat kanserli ve benign prostat hiperplazili hastalarda, prostat görünür difüzyon katsayısı (ADC) değerlerini hesaplamak ve kıyaslamaktır. Gereç ve yöntem: 20 prostat kanserli ve 20 benign prostat hiperplazili hastadan, difüzyon ağırlıklı eko-planar (EPI) görüntüler alınmıştır. Her iki hasta grubunda b600 ve b1000 değerleri için ayrı ayrı ADC ölçümleri gerçekleştirilmiştir. Bulgular: Prostat kanserli hasta grubunun prostatlarından, prostat biyopsi sonuçlarının kılavuzluğunda elde edilen ortalama ADC değerleri, b600 ve b1000 değerleri için sırasıyla 1.16x10-3±0.66x10-4 mm2/s ve 1.87x10-4±2.09x10-5 mm2/s olarak bulundu. Benign prostat hiperplazili hasta grubunun prostatlarından, randomize anatomik prostat lokalizasyonu seçimi ile elde edilen ortalama ADC değerleri ise b600 ve b1000 değerleri için sırasıyla 1.71x10-3±1.96x10-4mm2/s ve 2.90x10-4±1.58x10-5 mm2/s olarak bulundu. Hem b600 hem de b1000 değerleri için prostat kanserli hastaların prostatlarından elde edilen ADC değerleri, benign prostat hiperplazili hastaların prostatlarından elde edilen ADC değerlerine göre anlamlı biçimde düşük bulunmuştur. Sonuç: Prostatın difüzyon ağırlıklı eko-planar görüntülemesi ve ADC ölçümleri, prostat kanseri ile benign prostat hiperplazisinin ayırıcı tanısında önemli bilgiler sağlamıştır.

🔖

Cite This Article

PİRİNÇCİ, N., OZAN, T., FIRDOLAŞ, F., KOÇ, M., KARAKEÇİ, A., YALÇIN, O. (2022). The Use of Diffusion Weighted Magnetic Resonance Imaging in The Differential Diagnosıs of Prostate Cancer and Benign Prostatic Hyperplasia. Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi, Cilt: 31 - Sayı: 1, 19–24. https://ajindex.com/articles/514561

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99-166
  2. Donovan JL, Kay HE, Peters TJ, et al. Using the ICSQoL to measure the impact of lower urinary tract symptoms on quality of life: Evidence from the ICS-BPH study. International Continence Society-Benign Prostatic Hyperplasia. Br J Urol 1997; 80: 712-721
  3. Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: Prospective study in 66 patients. Radiology 2003; 226: 71-78
  4. Grenier N, Basseau F, Ries M, Tyndal B, Jones R, Moonen C. Functional MRI of the kidney. Abdom Imaging 2003; 28: 164-175
  5. Guo Y, Cai YQ, Cai ZL, et al. Differentiation of clinically benign and malignant breast lesions using diffusionweighted imaging. J Magn Reson Imaging 2002; 16: 172- 178
  6. Hosseinzadeh K, Schwarz SD. Endorectal diffusionweighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging 2004; 20: 654-661
  7. White S, Hricak H, Forstner R. Prostate cancer: Effect of postbiopsy hemorrhage on interpretation of MR images. Radiology 1995; 195: 385-390
  8. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: Interpreting trends in prostate cancer. J Natl Cancer Inst 1999; 91: 1017
  9. Merrill RM, Stephenson RA. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening. J Urol 2000; 163: 503
  10. Thompson I, Carroll P, Coley C. Prostate specific antigen best practice policy. Oncology 2000; 14: 267
  11. Le Bihan D, Breton E, Lallemand D, et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168: 497-505
  12. Le Bihan D, Turner R, Douek P, Patronas N. Diffusion MR imaging: clinical applications. AJR 1992;159: 591-599
  13. Thoeny HC, De Keyzer F, Oyen RH, Peeters RR. Diffusion-weighted MR imaging of kidneys in healthy volunteers and patients with parenchymal diseases: İnitial experience. Radiology 2005; 235: 911-917
  14. Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by ADC values in transition and peripheral zones of prostate. Journal of MRI 2005; 21: 258-262
  15. Gibbs P, Pickles MD, Turnbull LW. Diffusion Imaging of the Prostate at 3.0 Tesla. Invest Radiol 2006;41: 185-188. 16.